N&PD Moderators: Skorpio | someguyontheinternet
does 5HT1A agonism play a reasonable role in MDMA's empathogenic effects?
(...)
A weak partial agonist would still displace MDMA off 5ht1a receptors. If it has less intrinsic activity than MDMA at the site, a difference in response should be measurable.^ that study has some serious problems. For one Pindolol acts as a 5-HT1A partial agonist, not an antagonist, so it doesn't make much sense to reverse a 5-HT1A mediated effect with that drug.
A weak partial agonist would still displace MDMA off 5ht1a receptors. If it has less intrinsic activity than MDMA at the site, a difference in response should be measurable.
^ that study has some serious problems. For one Pindolol acts as a 5-HT1A partial agonist, not an antagonist, so it doesn't make much sense to reverse a 5-HT1A mediated effect with that drug.
the fact that administering an opioid antagonist (naloxone or naltrexone) to opioid naive individuals seems to have no effect.
wouldn't the antagonist block the effect of endogenous opioids, thus causing dysphoria or even symptoms similar to mild precipitated withdrawal?
If cells were secreted opioid antagonists people would be able to collect those compounds and test them on control cells.it would seem to make as much sense that the body produces its own endogenous opioid antagonists, in proportion to how much activity is detected at the receptors.
That's untrue. If you give a sober person a shot of naloxone they'll almost assuredly feel like crap.
My best attempt at an analogy is that the brain's opioid receptors can be thought of as a bundle of fiber-optic threads. Normally a small little light shines (endogenous production) that keeps us feeling okay. When we take a shot of heroin, it is like pointing a huge floodlight at the strands, and this causes our brain to adapt by removing or disabling many of the strands, and by shutting off the little light (endogenous production). After a while, when heroin use is stopped, the light is off or very dim, and the number of fiber-optic strands are so few that almost no light is getting through, thus we experience withdrawal, until the brain adapts by upregulating (adding / enabling more fibers) and increasing the little light output to previous levels so that we feel normal again.
The release of opioid peptides from enteric neurons can be accompanied by substantial changes in motility and secretion (8, 43). The inhibitory effect of opioid agonists is related to interruption of neurotransmission within the enteric nerve pathways governing gut muscle activity (8, 46, 47, 48). Opioid receptor agonists can interrupt both excitatory and inhibitory neural inputs to the musculature of the gastrointestinal tract; inhibition of excitatory pathways inhibits the release of excitatory neurotransmitters, such as acetylcholine, and blocks distension-induced peristaltic contractions (Figure 2). In contrast, blockade of inhibitory neurotransmission results in suppression of nitric oxide release from inhibitory motor neurons, disinhibition of gastrointestinal muscle activity, elevation of resting muscle tone, as well as nonpropulsive motility (7, 8). Because opioid receptor agonists can influence both excitatory and inhibitory activity, as well as activate the interstitial cell–muscle network, their effects on gastrointestinal motility and secretion can be complex. μ-Opioid receptor agonists inhibit gastric emptying, increase pyloric muscle tone, induce pyloric and duodenojejunal phasic pressure activity, disturb the migrating motor complex, delay transit through the small and large intestine, and elevate resting and sphincter pressure (8). In addition, the μ-opioid receptor agonists inhibit gastrointestinal ion and fluid transport (Figure 2). As a result of the combination of prolonged contact of the intestinal contents with the mucosa and interruption of prosecretory enteric reflexes, opioids attenuate the secretion of electrolytes and water and facilitate the net absorption of fluid (8).
The effects of μ-opioid receptor agonists on the gut are mediated by interaction with enteric μ-opioid receptors. The transduction of a signal through these receptors can result in activation of a number of pathways, including activation of potassium channels, membrane hyperpolarization, inhibition of calcium channels, and reduced production of cyclic adenosine monophosphate (8). All three classes of opioid receptors—δ, κ, and μ—have been shown to contribute to opioid-induced inhibition of muscle activity in isolated human intestinal tissues (5).